<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163824</url>
  </required_header>
  <id_info>
    <org_study_id>KPI-121-C-001</org_study_id>
    <nct_id>NCT02163824</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation</brief_title>
  <acronym>Hawaii-1</acronym>
  <official_title>A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kala Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kala Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the efficacy and safety of KPI-121
      ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
      The efficacy and safety of two different concentrations and two different dosing regimens of
      KPI-121 are also being assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, multicenter, double-masked, randomized, placebo-controlled,
      parallel-group study designed to evaluate the efficacy and safety of two doses and two dosing
      regimens of KPI-121 ophthalmic suspension versus placebo in subjects who require treatment of
      postoperative anterior ocular inflammation.

      Approximately 500 subjects will be screened and up to 402 subjects with one study eye each
      will be randomized in this study at approximately 25 centers located in the United States.
      Subjects who experience postoperative inflammation on the first day following routine,
      uncomplicated, cataract surgery and who meet all other eligibility criteria will be
      randomized to one of four study groups (0.25% four times daily or 1.0% two times daily) or
      Placebo A four times daily or Placebo B two times daily. Drug product or placebo will be
      initiated on the day following surgery and instilled as one to two drops in the study eye
      according to the assigned dosing regimen for 14 days.

      This study will include up to 7 clinic visits (including the surgery day) over 18 to 33 days
      total study duration. Visit 1 (Screening) will occur between 14 to 1 day(s) prior to surgery,
      and subjects who meet preoperative screening inclusion/exclusion criteria will be entered
      into the study. At Visit 2 (Surgery/Day 0) subjects will undergo routine cataract surgery
      according to the Investigator's normal procedures. Visit 3 (Randomization/Day 1) will occur
      on the day following surgery.

      Following randomization, subjects will be instructed to return to the clinic to be evaluated
      at Visit 4 (Day 3 +2 day), Visit 5 (Day 8 ±1 day), and Visit 6 (Day 15 ±1 day). The last dose
      of study product will be administered upon completion of 14 days of evaluation. Following the
      End of Study Product Use Visit (Visit 6; Day 15 ±1 day), subjects will be asked to return to
      the clinic on Day 17-19 for Visit 7 (Follow-Up) and will be released from the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of Anterior Chamber Cells</measure>
    <time_frame>Visit 5 (postoperative day 8)</time_frame>
    <description>Subjects with complete resolution of anterior chamber cells (cell score = 0) in the study eye at Visit 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resolution of Ocular Pain</measure>
    <time_frame>Visit 5 (postoperative day 8)</time_frame>
    <description>Subjects with resolution of ocular pain (grade = 0) in the study eye at Visit 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resolution of Ocular Pain</measure>
    <time_frame>Visit 6 (postoperative day 15)</time_frame>
    <description>Subjects with resolution of ocular pain (grade = 0) in the study eye at Visit 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resolution of Anterior Chamber Cells</measure>
    <time_frame>Visit 6 (postoperative day 15)</time_frame>
    <description>Subjects with complete resolution of anterior chamber cells (cell score = 0) in the study eye at Visit 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of both Anterior Chamber Cell and Ocular Pain</measure>
    <time_frame>Visit 5 (postoperative day 8)</time_frame>
    <description>Subjects with complete resolution (grade = 0) of anterior chamber cells complete resolution (grade = 0) of ocular pain at Visit 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of both Anterior Chamber Cells and Ocular Pain</measure>
    <time_frame>Visit 6 (postoperative day 15)</time_frame>
    <description>Subjects with complete resolution (grade = 0) of anterior chamber cells and complete resolution (grade = 0) of ocular pain at Visit 6</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">380</enrollment>
  <condition>Ocular Infections, Irritations and Inflammations</condition>
  <arm_group>
    <arm_group_label>KPI-121 0.25% QID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KPI-121 1.0% BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo A QID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo B BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KPI-121</intervention_name>
    <description>KPI-121 drug product will be supplied in two strengths: 0.25% and 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.</description>
    <arm_group_label>KPI-121 0.25% QID</arm_group_label>
    <arm_group_label>KPI-121 1.0% BID</arm_group_label>
    <other_name>KPI-121 0.25% Ophthalmic Suspension</other_name>
    <other_name>KPI-121 1.0% Ophthalmic Suspension</other_name>
    <other_name>Loteprednol etabonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of KPI-121 Ophthalmic Suspension</intervention_name>
    <description>Vehicle of KPI-121 0.25% Ophthalmic Suspension will be dosed QID (Placebo A), Vehicle of KPI-121 1.0 % Ophthalmic Suspension will be dosed BID (Placebo B).</description>
    <arm_group_label>Placebo A QID</arm_group_label>
    <arm_group_label>Placebo B BID</arm_group_label>
    <other_name>Vehicle of KPI-121 0.25% Ophthalmic Suspension</other_name>
    <other_name>Vehicle of KPI-121 1.0% Ophthalmic Suspension</other_name>
    <other_name>Placebo A</other_name>
    <other_name>Placebo B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        FURTHER STUDY DETAILS PROVIDED BY KALA PHARMACEUTICALS, INC.

        Inclusion Criteria:

          -  Candidates for routine, uncomplicated cataract surgery

          -  In Investigator's opinion, potential postoperative Snellen Distance VA by pinhole
             method of at least 20/200 in study eye.

        Exclusion Criteria:

          -  Known hypersensitivity/contraindication to study product(s) or components.

          -  History of glaucoma, IOP &gt;21 mmHg at the screening or randomization visits, or being
             treated for glaucoma in either eye.

          -  Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in
             judgment of Investigator could confound study assessments or limit compliance;
             severe/serious systemic disease or uncontrolled medical condition that in judgment of
             Investigator could confound study assessments or limit compliance; or have been
             exposed to an investigational drug within the 30 days prior to screening or 19 days
             following surgery.

          -  In the opinion of Investigator or study coordinator, be unwilling or unable to comply
             with study protocol or unable to successfully instill eye drops.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranjan Malhotra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raymond Fong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Raymond Fong, MDPC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Gira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmology Consultants</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damien Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wolstan &amp; Goldberg Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Hartman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rochester Ophthalmological Group, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Martel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martel Eye Medical Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Milstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Eye Clinic of Texas, affiliate Houston Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sebastian Mora, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kozlovsky Delay &amp; Winter Eye Consultants, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francis Price, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Price Vision Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Reilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>R&amp;R Eye Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Smyth-Medina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Valley Eye Medical Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Tauber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tauber Eye Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lloyd Taustine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taustine Eye Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nevin Tekwani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tekwani Vision Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert DaVanzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornerstone Eye Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Sall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sall Research Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Wilson, OD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John-Kenyon American Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Derick DelMonte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alice Epitropoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Eye Center of Columbus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas Lorenz, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westfield Nevada Eye and Ear</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Nordlund, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Roel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westside Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Sheppard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Eye Consultants</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harvey B Dubiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clayton Eye Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sall Research Medical Center</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Valley Eye Medical Group</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martel Eye Medical Group</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolstan &amp; Goldberg Eye Associates</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clayton Eye Center</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John-Kenyon American Eye Institute</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taustine Eye Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tauber Eye Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekwani Vision Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Consultants</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Physicians Research Group</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raymond Fong, MDPC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Ophthalmological Group, PC</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornerstone Eye Care</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Center of Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Research, LLC</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Clinic of Texas, Affiliate of Houston Eye Associates</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R&amp;R Eye Research, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kozlovsky Delay &amp; Winter Eye Consultants, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Eye Consultants</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <disposition_first_submitted>June 30, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 30, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 4, 2016</disposition_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postsurgical</keyword>
  <keyword>postoperative</keyword>
  <keyword>ocular</keyword>
  <keyword>cataract</keyword>
  <keyword>inflammation</keyword>
  <keyword>pain</keyword>
  <keyword>corticosteroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Eye Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

